Obalon Therapeutics, Inc.

Obalon Therapeutics, Inc. is a medical device company focused on innovative solutions for weight management, notably through its FDA-approved Obalon Balloon System designed for individuals with obesity. Obalon Therapeutics, Inc. specializes in non-surgical weight-loss solutions, primarily through the Obalon Balloon System.

Founded in 2008 and headquartered in Carlsbad, California, the company has undergone significant funding rounds, including a PIPE round raising USD 10. 00 mn, with backing from Domain Associates and InterWest Partners. The company raised USD 75 mn in its IPO on October 5, 2016, selling 5 million shares at USD 15 per share. The founder's history includes previous ventures, contributing to the expertise driving Obalon's offerings.

Obalon Therapeutics, Inc. offers the Obalon Balloon System, an FDA-approved swallowable, gas-filled balloon for adults with a BMI of 30 to 40 kg/m², used in conjunction with a structured diet and exercise plan. Additionally, the ReShape Gastric Vest is part of their product range, targeting similar demographics. Both solutions primarily cater to the North American market, providing less invasive alternatives to traditional bariatric surgery.

In the most recent fiscal year, 2024, Obalon Therapeutics generated revenue of USD 8. 01 mn with an EBITDA of USD -7. 71 mn. The revenue primarily originates from direct sales to healthcare providers and patients, facilitated through distribution partnerships with specialized weight-loss management facilities.

Obalon Therapeutics plans to enhance its product portfolio with additional weight-loss solutions designed for diverse demographics. The company aims to expand its market presence into international regions, specifically targeting Europe and Asia by 2025. Recent funding will be utilized to support research, development, and marketing initiatives for new product launches and to strengthen distribution channels as it seeks to build upon its existing customer base.